Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MSCI Australia ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while iShares MSCI Australia ETF trades at $28.47 (market cap $1.17B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 12.2× iShares MSCI Australia ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares MSCI Australia ETF for 63 Days on average.
| CRL | EWA | |
|---|---|---|
Market Cap | $14.23B | $1.17B |
Volume | 1,176,885 | 2,121,231 |
Sector | Health | Broad Market / Factor |
52-Week High | $310.77 | $30.43 |
52-Week Low | $149.93 | $24.95 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
EWA, the iShares MSCI Australia ETF, trades at $28.23, down 1.12% amid broader Australian market weakness. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent institutional activity includes Squarepoint Ops reducing its stake by 91.2% while other firms like Empowered Funds and Cetera Investment Advisers increased positions. The ETF serves as a commodity proxy, benefiting from Australia's export-driven economy.
The outlook remains cautious with technical weakness and mixed institutional sentiment. Upside potential exists if commodity demand drives Australian equities higher, but near-term risks include persistent inflation concerns and tight monetary policy. The Seeking Alpha buy rating targeting $34.83 suggests over 20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
